Satiereal® (Standardized Saffron Extract for Snacking Control)

Crocus sativus
Evidence Level
Limited
2 Clinical Trials
4 Documented Benefits
2/5 Evidence Score

Satiereal® is a standardized saffron stigma extract developed by Inoreal for appetite and snacking-control support. Distinct from generic saffron extracts and from mood-focused branded saffron variants such as Affron® and Safr'Inside, Satiereal® was characterized in an 8-week randomized, double-blind, placebo-controlled trial in mildly overweight women, where 176.5 mg/day reduced snacking frequency and produced modest reductions in body weight versus placebo. A separate trial in patients with diagnosed coronary artery disease reported reduced appetite and dietary intake, but it used a generic saffron aqueous extract and crocin rather than Satiereal®, so its findings are not attributable to this branded extract. The evidence base is small but specifically supports a snacking-control positioning rather than significant standalone weight loss, and should be framed honestly within those limits.

Studied Dose The single brand-specific trial (Gout 2010) used 176.5 mg/day of Satiereal® saffron extract for 8 weeks in 60 mildly overweight women, dosed as a single daily capsule.
Active Compound Standardized saffron (Crocus sativus) stigma extract; standardized for safranal and crocins; branded as Satiereal® by Inoreal.

Benefits

Helps reduce snacking frequency

One 8-week randomized, double-blind, placebo-controlled trial of Satiereal® in 60 mildly overweight women — the only trial of the branded material, conducted with manufacturer (Inoreal) involvement — reported a reduction in snacking frequency between meals versus placebo. It has not been independently replicated. The effect is the most distinctive feature of this saffron extract within the weight-management space.

Supports satiety and reduced grazing

In that same single 60-woman trial, participants self-reported greater satiety and less between-meal grazing on Satiereal®. These are subjective outcomes from one small study, not a separate line of evidence. The ingredient is positioned as a satiety-and-snacking-control adjunct rather than a primary weight-loss intervention.

Modest body weight changes alongside lifestyle support

The single 60-woman Satiereal® trial reported modest reductions in body weight versus placebo over 8 weeks. That is one small, unreplicated brand-specific result — the only other cited trial used generic saffron and crocin in coronary artery disease patients — so it should not be read as a consistent weight-loss finding. Effect sizes are small and best framed as an adjunct to diet and lifestyle support.

May support mood-related eating patterns

Mood research on saffron has used different saffron preparations (such as Affron®) and is not cited on this page, and no mood outcome was measured in the Satiereal® snacking trial. The idea that part of the appetite effect is mediated through mood-related eating patterns such as emotional snacking is a hypothesis about mechanism, not a demonstrated effect of this branded extract.

Mechanism of action

1

Serotonergic modulation

Crocins and safranal from saffron influence central serotonergic signalling, which is closely tied to satiety and appetite regulation as well as mood. This is the most commonly proposed mechanism for the snacking-control effect seen in the single Satiereal® trial, but it has not been directly measured in people taking this extract.

2

Dopaminergic / reward pathway modulation

Saffron constituents have been described as modulating dopaminergic signalling in preclinical models, which may dampen reward-driven snacking behavior — particularly relevant for between-meal grazing and emotional eating patterns.

3

Hypothalamic appetite signalling

Saffron's bioactive carotenoids may interact with central appetite regulators in the hypothalamus, which has been proposed as one explanation for the reduced snacking and higher self-reported satiety seen in the single Satiereal® trial, though this pathway was not measured in that study.

Clinical trials

1
Satiereal® 8-Week Snacking-Control RCT (Gout et al. 2010)

Randomized, double-blind, placebo-controlled trial of Satiereal® saffron extract (176.5 mg/day) vs placebo in 60 mildly overweight, healthy women over 8 weeks. Outcomes: snacking frequency, subjective satiety, body weight, BMI.

60 mildly overweight healthy women; 8-week intervention.

Satiereal® significantly reduced snacking frequency between meals vs placebo and produced modest reductions in body weight. This is the only trial of the branded material and was conducted with manufacturer (Inoreal) involvement. The small sample (n=60), single-sex healthy population, 8-week duration, and absence of independent replication are key limitations, so it is best read as preliminary support for a snacking-control positioning rather than as a weight-loss result.

2
Saffron and Crocin for Appetite and Body Composition in CAD Patients

8-week randomized, double-blind, placebo-controlled trial of generic saffron aqueous extract and crocin — not Satiereal® — in 84 patients with coronary artery disease. Outcomes: appetite, dietary intake, body composition.

84 coronary artery disease patients; 8-week intervention.

Both saffron extract and crocin reduced appetite and dietary intake vs placebo, with saffron showing greater effects on central obesity measures. Important limitation: this trial tested a generic saffron aqueous extract and crocin — not Satiereal® — in patients with diagnosed coronary artery disease. It is a different material in a disease population, so the results cannot be attributed to Satiereal® or generalized to otherwise healthy adults.

Side effects and drug interactions

Common Potential side effects

Generally well tolerated at studied doses (≤200 mg/day).
Mild gastrointestinal discomfort or nausea occasionally reported.
Headache occasionally reported in saffron trials.
Avoid high doses in pregnancy due to traditional concerns about uterine activity.
Limited long-term safety data beyond trial durations.

Important Drug interactions

Antidepressants (SSRIs, MAOIs) — saffron has mild serotonergic effects; combine with clinician guidance.
Anticoagulants (warfarin) — possible modest platelet effects with high-dose saffron; monitor.
Antihypertensive medications — saffron may modestly influence blood pressure; monitor.
Sedatives — possible additive calming effects at higher saffron doses.

Frequently asked questions about Satiereal® (Standardized Saffron Extract for Snacking Control)

What is Satiereal?

Satiereal® is a standardized saffron stigma extract developed by Inoreal for appetite and snacking-control support. Distinct from generic saffron extracts and from mood-focused branded saffron variants such as Affron® and Safr'Inside, Satiereal® was characterized in an 8-week randomized, double-blind, placebo-controlle…

What is Satiereal used for?

Satiereal is researched primarily for Weight Management and Mood & Mental Health. One 8-week randomized, double-blind, placebo-controlled trial of Satiereal® in 60 mildly overweight women — the only trial of the branded material, conducted with manufacturer (Inoreal) involvement — reported a reduction in snacking frequen…

What is the recommended dosage of Satiereal?

The clinically studied dose is The single brand-specific trial (Gout 2010) used 176.5 mg/day of Satiereal® saffron extract for 8 weeks in 60 mildly overweight women, dosed as a single daily capsule. Always follow the product label and check with a healthcare provider for personal advice.

Is Satiereal safe, and does it have side effects?

For most healthy adults, Satiereal is well tolerated at studied doses. Reported effects can include: Generally well tolerated at studied doses (≤200 mg/day). Mild gastrointestinal discomfort or nausea occasionally reported. It may also interact with some medications. Satiereal is not right for everyone, so check with a healthcare provider first if you are pregnant or breastfeeding, have a medical condition, or take prescription medication.

Does Satiereal interact with any medications?

Possible interactions include: Antidepressants (SSRIs, MAOIs) — saffron has mild serotonergic effects; combine with clinician guidance. Anticoagulants (warfarin) — possible modest platelet effects with high-dose saffron; monitor. If you take prescription medication, check with a pharmacist or doctor before using it.

How strong is the scientific evidence for Satiereal?

NutraSmarts rates the evidence for Satiereal as Limited (2 out of 5). It is backed by 2 clinical trials and 2 cited references summarized on this page. A higher rating reflects more, larger, and better-designed human studies.

References(2 citations)

Evidence ratings on NutraSmarts are based on the totality of human clinical research, with emphasis on randomized controlled trials, meta-analyses, and systematic reviews. The references below directly support claims made throughout this page.

  1. Gout B, Bourges C, Paineau-Dubreuil S. Satiereal, a Crocus sativus L extract, reduces snacking and increases satiety in a randomized placebo-controlled study of mildly overweight, healthy women. Nutr Res. 2010;30(5):305-13. doi: 10.1016/j.nutres.2010.04.008.PubMedUsed to support: Single manufacturer-linked (Inoreal) 8-week RCT of Satiereal® (176.5 mg/day) in 60 mildly overweight women — the only trial of the branded extract, not independently replicated — significant reductions in snacking frequency and modest reductions in body weight vs placebo. Establishes Satiereal® as a snacking-control rather than primary weight-loss ingredient.
  2. Abedimanesh N, Bathaie SZ, Abedimanesh S, Motlagh B, Separham A, Ostadrahimi A. Saffron and crocin improved appetite, dietary intakes and body composition in patients with coronary artery disease. J Cardiovasc Thorac Res. 2017;9(4):200-208. doi: 10.15171/jcvtr.2017.35.PubMedUsed to support: 8-week RCT in 84 coronary artery disease patients — saffron extract and crocin reduced appetite and dietary intake vs placebo, with saffron showing greater effects on central obesity measures. Tested generic saffron aqueous extract and crocin — not Satiereal® — in a diagnosed coronary artery disease population, so it speaks to saffron constituents generally and is not evidence for this branded extract.